Hypocalcemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Calcium, the third most prevalent ion in the body, plays a crucial role in maintaining various physiological functions, including cellular homeostasis, neural transmission, membrane integrity, blood clotting, intracellular signaling, and skeletal structure integrity. In plasma, calcium exists in three primary forms: ionized (the biologically active form), protein-bound (mainly to albumin), and complexed to anions like bicarbonate, lactate, phosphate, and citrate. Hypocalcemia, characterized by low levels of total serum calcium (<8.5 mg/dL) or ionized serum calcium (<4.7 mg/dL), results from a net efflux of calcium from the extracellular fluid exceeding the rate of replacement by intestines or bones. Neurological manifestations are predominant in hypocalcemia due to increased neuronal membrane excitability. Symptoms include altered mental status, confusion, depression, psychosis, gait disturbances, muscle twitching, paresthesias, tremors, seizures, muscle rigidity, and tetany. Clinical signs such as the Trousseau sign may also be observed, indicating latent tetany. Cardiac effects, like prolongation of the QT interval, often manifest early. Prolonged hypocalcemia may lead to subcapsular cataracts and calcifications in brain regions such as the basal ganglia, cerebral cortex, and cerebellum, occasionally resulting in Parkinsonism, choreoathetosis, or dysphonic spasms. Treatment involves calcium and vitamin D supplementation, especially in symptomatic patients. Chronic hypocalcemia can be asymptomatic or present with subtle symptoms, while even a mild acute reduction in serum calcium levels can precipitate severe symptoms.
Thelansis’s “Hypocalcemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypocalcemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hypocalcemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hypocalcemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment